Misonix, Inc. (NASDAQ:MSON) VP Joseph J. Brennan sold 8,357 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $15.91, for a total value of $132,959.87. Following the completion of the transaction, the vice president now directly owns 5,649 shares of the company’s stock, valued at $89,875.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of MSON stock remained flat at $$16.50 during trading hours on Friday. The stock had a trading volume of 10,918 shares, compared to its average volume of 19,555. Misonix, Inc. has a twelve month low of $8.25 and a twelve month high of $21.43.
Misonix (NASDAQ:MSON) last announced its earnings results on Thursday, November 8th. The medical equipment provider reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.09). The business had revenue of $9.36 million for the quarter. Misonix had a negative return on equity of 14.05% and a negative net margin of 23.24%.
A number of research analysts have issued reports on MSON shares. TheStreet downgraded Misonix from a “c” rating to a “d+” rating in a report on Friday, September 7th. Canaccord Genuity began coverage on Misonix in a research note on Friday, August 24th. They set a “buy” rating and a $24.00 target price for the company. Craig Hallum began coverage on Misonix in a research note on Tuesday, September 11th. They set a “buy” rating and a $28.00 target price for the company. Finally, ValuEngine downgraded Misonix from a “buy” rating to a “hold” rating in a research note on Friday.
Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Misonix by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock worth $3,941,000 after buying an additional 28,889 shares during the period. Nordea Investment Management AB acquired a new position in shares of Misonix during the 3rd quarter worth approximately $649,000. Manatuck Hill Partners LLC acquired a new position in shares of Misonix during the 3rd quarter worth approximately $329,000. Renaissance Technologies LLC raised its stake in shares of Misonix by 10.8% during the 3rd quarter. Renaissance Technologies LLC now owns 231,899 shares of the medical equipment provider’s stock worth $4,290,000 after buying an additional 22,599 shares during the period. Finally, Bridgeway Capital Management Inc. raised its stake in shares of Misonix by 24.3% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 68,100 shares of the medical equipment provider’s stock worth $1,260,000 after buying an additional 13,300 shares during the period. 15.93% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Misonix, Inc. (MSON) VP Sells 8,357 Shares of Stock” was originally reported by Equities Focus and is owned by of Equities Focus. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.equitiesfocus.com/2018/12/08/insider-selling-misonix-inc-mson-vp-sells-8357-shares-of-stock.html.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.